Comparative Pharmacology
Head-to-head clinical analysis: M ZOLE 7 DUAL PACK versus MONISTAT 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: M ZOLE 7 DUAL PACK versus MONISTAT 3.
M-ZOLE 7 DUAL PACK vs MONISTAT 3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
M-ZOLE 7 DUAL PACK contains miconazole, an imidazole antifungal that inhibits fungal lanosterol 14α-demethylase (CYP51), blocking ergosterol synthesis, disrupting fungal cell membrane integrity, and increasing permeability, leading to cell death.
Miconazole nitrate, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Adults: One vaginal tablet (containing 500 mg metronidazole and 150 mg miconazole nitrate) inserted vaginally once daily at bedtime for 7 days.
One vaginal suppository (200 mg miconazole nitrate) intravaginally at bedtime for 3 consecutive days; or one applicatorful (5 g) of 4% vaginal cream intravaginally at bedtime for 7 days.
None Documented
None Documented
Terminal half-life approximately 48–72 hours. Prolonged in renal impairment (up to 72–120 hours in ESRD), requiring dose adjustment.
Terminal elimination half-life is approximately 30 hours after topical vaginal application; prolonged in hepatic impairment.
Primarily renal (80% unchanged drug, 20% as metabolites); biliary/fecal excretion is minimal (<5%).
Primarily fecal (97%) via biliary excretion; renal excretion of unchanged drug is negligible (<1%).
Category C
Category C
Antifungal
Antifungal